Drug interactions with solid tumour-targeted therapies

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 179-196

  Thomas Schoemann, Audrey ^a,b   Blanchet, Benoit ^a,b   Bardin, Christophe ^b   Noé, Gaëlle ^b   Boudou Rouquette, Pascaline ^a,d   Vidal, Michel ^a,b,c   Goldwasser, François ^a,d  

^a Centre d'Étude et de Recours aux Inhibiteurs de l'Angiogénèse   (France)

^b Laboratoire de Pharmacochimie   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Drug drug interactions; Herb drug interactions; Mammalian target of rapamycin inhibitors; Pharmacokinetics; Solid tumour; Targeted therapies; Tyrosine kinase inhibitors

Indexed keywords

APREPITANT; CARBOPLATIN; CIPROFLOXACIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FELODIPINE; FENOFIBRATE; FIRTECAN; FLUCONAZOLE; GEFITINIB; GREEN TEA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; KETOCONAZOLE; LAPATINIB; PACLITAXEL; RANITIDINE; RAPAMYCIN; RIFAMPICIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TOPOTECAN; UNINDEXED DRUG; VORICONAZOLE; CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; OMEPRAZOLE; PHENYTOIN;

AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; HUMAN; IN VITRO STUDY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADVANCED CANCER; ALTERNATIVE MEDICINE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TRANSPORT; FOOD INTAKE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HYPERICUM PERFORATUM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PANCREAS METASTASIS; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN BINDING; PROTEIN TARGETING; THROMBOCYTOPENIA;

5-FLUOROURACILE; 5FU; ABC; AREA UNDER THE CURVE; ATP-BINDING CASSETTE; AUC; BCRP; BREAST CANCER RESISTANCE PROTEIN; C(MAX); CYP; CYTOCHROME P450 ENZYMES; DDI; DRUG-DRUG INTERACTIONS; EIAEDS; ENZYME-INDUCING ANTIEPILEPTIC DRUGS; HERB-DRUG INTERACTIONS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS; MAXIMUM (PEAK) PLASMA CONCENTRATION; MTOR; P-GLYCOPROTEIN; P-GP; PHARMACOKINETICS; SOLID TUMOUR; TARGETED THERAPIES; TKI; TYROSINE KINASE INHIBITOR; TYROSINE KINASE INHIBITORS; UDP-GLUCURONYL TRANSFERASE; UGT;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84890870031     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.007     Document Type: Review

References (204)

1. Scripture C.D., Figg W.D. Drug interactions in cancer therapy. Nat Rev Cancer 2006, 6:546-558.
2. Hornecker M., Blanchet B., Billemont B., et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs 2012, 30:1991-2000.
3. Tod M., Mir O., Bancelin N., et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011, 28:3199-3207.
4. Lathia C., Lettieri J., Cihon F., Gallentine M., Radtke M., Sundaresan P. Lack of effect of ketoconazole-mediated cyp3a inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006, 57:685-692.
5. Flaherty K.T., Lathia C., Frye R.F., et al. Interaction of sorafenib and cytochrome p450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011, 68:1111-1118.
6. Meza-Junco J., Chu Q.S., Christensen O., et al. Ugt1a1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009, 65:1-4.
7. Peer C.J., Sissung T.M., Kim A., et al. Sorafenib is an inhibitor of ugt1a1 but is metabolized by ugt1a9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012, 18:2099-2107.
8. Kane R.C., Farrell A.T., Madabushi R., et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009, 14:95-100.
9. Lagas J.S., van Waterschoot R.A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010, 9:319-326.
10. Hu S., Chen Z., Franke R., et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009, 15:6062-6069.
11. European Medicine Agency, 2007. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_scientific_discussion/human/000690/wc500027707.Pdf.
12. Lind J.S., Dingemans A.M., Groen H.J., et al. A multicenter phase ii study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:3078-3087.
13. Reardon D.A., Vredenburgh J.J., Desjardins A., et al. Effect of cyp3a-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011, 101:57-66.
14. Gomo C., Coriat R., Faivre L., et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs 2011, 29:1511-1514.
15. Vaishampayan U.N., Burger A.M., Sausville E.A., et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2011, 16:3795-3804.
16. Flaherty K.T., Schiller J., Schuchter L.M., et al. A phase i trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008, 14:4836-4842.
17. Okamoto I., Miyazaki M., Morinaga R., et al. Phase i clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 2010, 28:844-853.
18. Awada A., Hendlisz A., Christensen O., et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 2012, 48:465-474.
19. Duran I., Hotte S.J., Hirte H., Chen E.X., MacLean M., Turner S. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007, 13:4849-4857.
20. Quintela-Fandino M., Le Tourneau C., Duran I., Chen E.X., Wang L., Tsao M. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 2010, 9:751-760.
21. Adjei A.A., Molina J.R., Mandrekar S.J., et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007, 13:2684-2691.
22. Nabhan C., Villines D., Valdez T.V., et al. Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. Br J Cancer 2012, 107:592-597.
23. Harzstark A.L., Small E.J., Weinberg V.K., et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011, 117:4194-4200.
24. Desar I.M., Timmer-Bonte J.N., Burger D.M., van der Graaf W.T., van Herpen C.M. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br J Cancer 2010, 103:1637-1643.
25. Gangadhar T.C., Cohen E.E., Wu K., et al. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 2011, 17:1956-1963.
26. Mross K., Steinbild S., Baas F., et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007, 43:55-63.
27. Escudier B., Lassau N., Angevin E., et al. Phase I trial of sorafenib in combination with ifn alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007, 13:1801-1809.
28. Niwakawa M., Hashine K., Yamaguchi R., et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drugs 2011, 30:1046-1054.
29. Rosen L.S., Puzanov I., Friberg G., et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012, 18:3414-3427.
30. Shacham-Shmueli E., Geva R., Figer A., et al. Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. J Clin Pharmacol 2012, 52:656-669.
31. Awada A., Gil T., Whenham N., et al. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol 2011, 51:1674-1684.
32. Infante J.R., Jones S.F., Bendell J.C., et al. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol 2012, 69:137-144.
33. Kupsch P., Henning B.F., Passarge K., et al. Results of a phase i trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005, 5:188-196.
34. Brendel E., Ludwig M., Lathia C., et al. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 68:53-61.
35. Inaba H., Rubnitz J.E., Coustan-Smith E., et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011, 29:3293-3300.
36. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006, 12:144-151.
37. Schultheis B., Kummer G., Zeth M., et al. Phase Ib study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol 2012, 69:333-339.
38. Richly H., Henning B.F., Kupsch P., et al. Results of a phase i trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006, 17:866-873.
39. Liu Y., Ramirez J., Ratain M.J. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 2011, 71:917-920.
40. European Medicine Agency, 2007. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_scientific_discussion/human/000687/wc500057733.Pdf.
41. Tang S.C., Lagas J.S., Lankheet N.A., et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (Abcb1) and breast cancer resistance protein (Abcg2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2012, 130:223-233.
42. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. Sunitinib (Sutent, Su11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (Abc) transporters P-glycoprotein (Abcb1) and Abcg2. Drug Metab Dispos 2009, 37:359-365.
43. Hamberg P., Steeghs N., Loos W.J., et al. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br J Cancer 2010, 102:1699-1706.
44. van Erp N.P., Guchelaar H.J., Ploeger B.A., Romijn J.A., Hartigh J., Gelderblom H. Mitotane has a strong and a durable inducing effect on cyp3a4 activity. Eur J Endocrinol 2011, 164:621-626.
45. Blumenschein G.R., Ciuleanu T., Robert F., et al. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 2012, 7:1406-1416.
46. van Erp N.P., Baker S.D., Zandvliet A.S., et al. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 2011, 67:695-703.
47. Robert F., Sandler A., Schiller J.H., et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010, 66:669-680.
48. Yi J.H., Lee J., Lee J., et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012, 106:1469-1474.
49. Bergh J., Mariani G., Cardoso F., et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast 2012, 21:507-513.
50. Heath E.I., Blumenschein G.R., Cohen R.B., et al. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 2011, 68:703-712.
51. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
52. Cessot A.N.C., Thomas-Schoemann A., Boudou-Rouquette P., et al. How to predict sunitinib exposure and toxicity: a pharmacokinetic-pharmacodynamic study. J Clin Oncol 2013, 31. (suppl; abstr e15592).
53. Kozloff M., Chuang E., Starr A., et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010, 21:1436-1441.
54. Boven E., Massard C., Armand J.P., et al. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer 2010, 103:993-1000.
55. Molina A.M., Feldman D.R., Voss M.H., et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1868-1876.
56. Gomez-Martin C., Salazar R., Montagut C., et al. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs 2012.
57. Sweeney C.J., Chiorean E.G., Verschraegen C.F., et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010, 28:4513-4520.
58. Leong S., Eckhardt S.G., Chan E., et al. A phase I study of sunitinib combined with modified folfox6 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 70:65-74.
59. Starling N., Vazquez-Mazon F., Cunningham D., et al. A phase I study of sunitinib in combination with folfiri in patients with untreated metastatic colorectal cancer. Ann Oncol 2012, 23:119-127.
60. Motzer R.J., Hudes G.R., Ginsberg M.S. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2010, 33:614-618.
61. Reck M., Frickhofen N., Cedres S., et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer (Amsterdam, Netherlands) 2010, 70:180-187.
62. Okamoto I., Shimizu T., Miyazaki M., et al. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs 2011, 30:639-646.
63. Chow L.Q., Blais N., Jonker D.J., et al. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 2012, 69:709-722.
64. Rini B.I., Stein M., Shannon P., et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011, 117:758-767.
65. Grunwald V., Desar I.M., Haanen J., et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol 2011, 50:121-126.
66. Burris H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (gw572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
67. European Medicine Agency, 2008. http://www.emea.europa.eu/docs/en_gb/document_library/epar_-_product_information/human/000795/wc500044957.Pdf.
68. Kuang Y.H., Shen T., Chen X., et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (Abcc10)-mediated multidrug resistance. Biochem Pharmacol 2010, 79:154-161.
69. Polli J.W., Humphreys J.E., Harmon K.A., et al. The role of efflux and uptake transporters in [n-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (gw572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008, 36:695-701.
70. Dai C.L., Tiwari A.K., Wu C.P., et al. Lapatinib (tykerb, gw572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily b member 1 and g member 2. Cancer Res 2008, 68:7905-7914.
71. Perry J., Ghazaly E., Kitromilidou C., McGrowder E.H., Joel S., Powles T. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump bcrp. Mol Cancer Ther 2010, 9:3322-3329.
72. Chu C., Abbara C., Noel-Hudson M.S., et al. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in swiss mice. Biochem Pharmacol 2009, 77:1629-1634.
73. Dunne G., Breen L., Collins D.M., Roche S., Clynes M., O'Connor R. Modulation of p-gp expression by lapatinib. Invest New Drugs 2011, 29:1284-1293.
74. Smith D.A., Koch K.M., Arya N., Bowen C.J., Herendeen J.M., Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009, 67:421-426.
75. Thiessen B., Stewart C., Tsao M., et al. A phase I/II trial of gw572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010, 65:353-361.
76. Teo Y.L., Saetaew M., Chanthawong S., et al. Effect of cyp3a4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treatment 2012, 133:703-711.
77. Crown J.P.B.H., Jones S., Koch K.M., Fittipaldo A., Parikh R., Koehler M. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol 2007, 25. (abstract 1027).
78. Midgley R.S., Kerr D.J., Flaherty K.T., et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007, 18:2025-2029.
79. Brain E., Isambert N., Dalenc F., et al. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer 2012, 106:673-677.
80. Molina J.R., Kaufmann S.H., Reid J.M., et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008, 14:7900-7908.
81. Kimball K.J., Numnum T.M., Kirby T.O., et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008, 111:95-101.
82. Chu Q.S., Schwartz G., de Bono J., et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol 2007, 25:3753-3758.
83. Siegel-Lakhai W.S., Beijnen J.H., Vervenne W.L., et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (gw572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007, 13:4495-4502.
84. LoRusso P.M., Jones S.F., Koch K.M., et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008, 26:3051-3056.
85. Storniolo A.M., Pegram M.D., Overmoyer B., et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced Erbb2-positive breast cancer. J Clin Oncol 2008, 26:3317-3323.
86. Chu Q.S., Cianfrocca M.E., Goldstein L.J., et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 2008, 14:4484-4490.
87. Swaisland H.C., Smith R.P., Laight A., et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005, 44:1165-1177.
88. McKillop D., McCormick A.D., Miles G.S., et al. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 2004, 34:983-1000.
89. McKillop D., McCormick A.D., Millar A., Miles G.S., Phillips P.J., Hutchison M. Cytochrome p450-dependent metabolism of gefitinib. Xenobiotica 2005, 35:39-50.
90. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes. Clin Cancer Res 2007, 13:3731-3737.
91. Cohen M.H., Williams G.A., Sridhara R., et al. United States food and drug administration drug approval summary: gefitinib (zd1839; iressa) tablets. Clin Cancer Res 2004, 10:1212-1218.
92. Scheffler M., Di Gion P., Doroshyenko O., Wolf J., Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011, 50:371-403.
93. Li J., Cusatis G., Brahmer J., et al. Association of variant Abcg2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007, 6:432-438.
94. Ozvegy-Laczka C., Hegedus T., Varady G., et al. High-affinity interaction of tyrosine kinase inhibitors with the Abcg2 multidrug transporter. Mol Pharmacol 2004, 65:1485-1495.
95. Budha N.R., Frymoyer A., Smelick G.S., et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapyα. Clin Pharmacol Ther 2012, 92:203-213.
96. Swaisland H.C., Ranson M., Smith R.P., et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005, 44:1067-1081.
97. Chhun S., Verstuyft C., Rizzo-Padoin N., et al. Gefitinib-phenytoin interaction is not correlated with the c-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009, 68:226-237.
98. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12:860-868.
99. Cantarini M.V., Macpherson M.P., Marshall A.L., Robinson A.V., Bailey C.J. A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250mg oral dose of gefitinib (iressa) in healthy male volunteers. Cancer Chemother Pharmacol 2005, 56:557-562.
100. Milton D.T., Riely G.J., Azzoli C.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110:599-605.
101. Miller V.A., Johnson D.H., Krug L.M., et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003, 21:2094-2100.
102. O'Byrne K.J., Danson S., Dunlop D., et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007, 25:3266-3273.
103. Fakih M.G., Trump D.L., Muindi J.R., et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007, 13:1216-1223.
104. Meyerhardt J.A., Clark J.W., Supko J.G., et al. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2007, 60:661-670.
105. Ranson M., Shaw H., Wolf J., et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol 2010, 66:53-58.
106. European Medicine Agency, 2005. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_scientific_discussion/human/000618/wc500033991.Pdf.
107. Kodaira H., Kusuhara H., Ushiki J., Fuse E., Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 2010, 333:788-796.
108. Elmeliegy M.A., Carcaboso A.M., Tagen M., Bai F., Stewart C.F. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011, 17:89-99.
109. Shi Z., Peng X.X., Kim I.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily b member 1 and ATP-binding cassette subfamily g member 2-mediated drug resistance. Cancer Res 2007, 67:11012-11020.
110. European Medicine Agency, 2005. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_product_information/human/000618/wc500033994.Pdf.
111. Ter Heine R., Fanggiday J.C., Lankheet N.A., et al. Erlotinib and pantoprazole: a relevant interaction or notα. Br J Clin Pharmacol 2010, 70:908-911.
112. Abbas R., Fettner S., Riek M., et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc Am Soc Clin Oncol 2003, 22. (abstract).
113. van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009, 27:1268-1274.
114. Mir O., Blanchet B., Goldwasser F. Drug-induced effects on erlotinib metabolism. N Engl J Med 2011, 365:379-380.
115. Rakhit A., Pantze M.P., Fettner S., et al. The effects of cyp3a4 inhibition on erlotinib pharmacokinetics: computer-based simulation (simcyp) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008, 64:31-41.
116. Mir O., Blanchet B., Goldwasser F. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011, 364:487.
117. Vincenzi B., Tonini G., Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010, 363:397-398.
118. Grenader T., Gipps M., Shavit L., Gabizon A. Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer (Amsterdam, Netherlands) 2007, 57:404-406.
119. Veeraputhiran M., Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008, 9:232-234.
120. Thomas K.S., Billingsley A., Amarshi N., Nair B.A. Elevated international normalized ratio associated with concomitant warfarin and erlotinib. Am J Health Syst Pharm 2010, 67:1426-1429.
121. Messersmith W.A., Jimeno A., Jacene H., et al. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010, 9:297-304.
122. Messersmith W.A., Laheru D.A., Senzer N.N., et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004, 10:6522-6527.
123. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
124. Chiorean E.G., Porter J.M., Foster A.E., et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res 2008, 14:1131-1137.
125. Ranson M., Reck M., Anthoney A., et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 2010, 21:2233-2239.
126. Jakacki R.I., Hamilton M., Gilbertson R.J., et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children's oncology group phase I consortium study. J Clin Oncol 2008, 26:4921-4927.
127. Herbst R.S., Prager D., Hermann R., et al. Tribute: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
128. Peng B., Dutreix C., Mehring G., et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004, 44:158-162.
129. Gambacorti-Passerini C., Zucchetti M., Russo D., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-632.
130. Gschwind H.P., Pfaar U., Waldmeier F., et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005, 33:1503-1512.
131. Nebot N., Crettol S., d'Esposito F., Tattam B., Hibbs D.E., Murray M. Participation of cyp2c8 and cyp3a4 in the n-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 2010, 161:1059-1069.
132. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
133. Eechoute K., Sparreboom A., Burger H., et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011, 17:406-415.
134. Shen T., Kuang Y.H., Ashby C.R., et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009, 4:e7520.
135. Sparano B.A., Egorin M.J., Parise R.A., et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009, 63:525-528.
136. Egorin M.J., Shah D.D., Christner S.M., et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009, 68:370-374.
137. Bolton A.E., Peng B., Hubert M., et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004, 53:102-106.
138. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neurooncology 2008, 10:330-340.
139. Pursche S., Schleyer E., von Bonin M., et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008, 3:198-203.
140. Gambillara E., Laffitte E., Widmer N., et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005, 211:363-365.
141. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8:3034-3038.
142. Dutreix C., Peng B., Mehring G., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004, 54:290-294.
143. van Erp N.P., Gelderblom H., Karlsson M.O., et al. Influence of cyp3a4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007, 13:7394-7400.
144. O'Brien S.G., Meinhardt P., Bond E., et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3a4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003, 89:1855-1859.
145. Connolly R.M., Rudek M.A., Garrett-Mayer E., et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treatment 2011, 127:153-162.
146. Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005, 44:879-894.
147. de Groot J.W., Zonnenberg B.A., Plukker J.T., van Der Graaf W.T., Links T.P. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005, 78:433-438.
148. Cholongitas E., Pipili C., Katsogridakis K., Relos K., Dasenaki M. Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2008, 61:1083-1084.
149. Wang Y., Zhou L., Dutreix C., et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008, 65:885-892.
150. Kim D.W., Tan E.Y., Jin Y., et al. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2011, 71:199-206.
151. European Medicine Agency, 2007. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_scientific_discussion/human/000799/wc500039915.Pdf.
152. Cai P., Tsao R., Ruppen M.E. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 2007, 35:1554-1563.
153. Zimmerman J.J. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004, 6:e28.
154. Anglicheau D., Pallet N., Rabant M., et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006, 70:1019-1025.
155. Minocha M., Khurana V., Qin B., Pal D., Mitra A.K. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-tor inhibitors. Int J Pharm 2012, 434:306-314.
156. Yacyshyn B.R., Bowen-Yacyshyn M.B., Pilarski L.M. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996, 43:449-455.
157. Gupta A., Dai Y., Vethanayagam R.R., et al. Cyclosporin a, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (Abcg2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006, 58:374-383.
158. Boni J., Leister C., Burns J., Cincotta M., Hug B., Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007, 47:1430-1439.
159. Galanis E., Buckner J.C., Maurer M., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2005, 23:5294-5304.
160. Marty F.M., Lowry C.M., Cutler C.S., et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2006, 12:552-559.
161. Jain A.K., Venkataramanan R., Fridell J.A., et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl 2002, 8:838-840.
162. Bottiger Y., Sawe J., Brattstrom C., et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001, 69:32-40.
163. Zimmerman J.J., Harper D., Getsy J., Jusko W.J. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4hours apart in healthy volunteers. J Clin Pharmacol 2003, 43:1168-1176.
164. Shayani S., Palmer J.M., Stiller T., et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transpl 2012, 47:291-293.
165. European Medicine Agency, 2007. http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_product_information/human/000799/wc500039912.Pdf.
166. Boni J., Abbas R., Leister C., et al. Disposition of desipramine, a sensitive cytochrome p450 2d6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009, 64:263-270.
167. Crowe A., Bruelisauer A., Duerr L., Guntz P., Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999, 27:627-632.
168. Jacobsen W., Serkova N., Hausen B., Morris R.E., Benet L.Z., Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transpl Proc 2001, 33:514-515.
169. Klumpen H.J., Beijnen J.H., Gurney H., Schellens J.H. Inhibitors of mTOR. Oncologist 2010, 15:1262-1269.
170. Kovarik J.M., Hartmann S., Figueiredo J., Rouilly M., Port A., Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002, 36:981-985.
171. Lefeuvre S., Rebaudet S., Billaud E.M., Wyplosz B. Management of rifamycins-everolimus drug-drug interactions in a liver-transplant patient with pulmonary tuberculosis. Transpl Int 2012, 25:e120-e123.
172. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Shenouda M., Schmouder R.L. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005, 45:514-518.
173. Kovarik J.M., Hsu C.H., McMahon L., Berthier S., Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001, 70:247-254.
174. Pea F., Baccarani U., Tavio M., et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008, 42:1711-1716.
175. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Shenouda M., Schmouder R.L. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 2005, 61:35-38.
176. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Allison M.J., Schmouder R.L. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005, 60:434-437.
177. Awada A., Cardoso F., Fontaine C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44:84-91.
178. Kovarik J.M., Hartmann S., Hubert M., et al. Pharmacokinetic and pharmacodynamic assessments of hmg-coa reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002, 42:222-228.
179. Vansteenkiste J., Solomon B., Boyer M., et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive bayesian dose-escalation model. J Thorac Oncol 2011, 6:2120-2129.
180. Deenen M.J., Klumpen H.J., Richel D.J., et al. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest New Drugs 2012, 30:1557-1565.
181. Morrow P.K., Wulf G.M., Ensor J., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29:3126-3132.
182. Tindle H.A., Davis R.B., Phillips R.S., Eisenberg D.M. Trends in use of complementary and alternative medicine by us adults: 1997-2002. Altern Ther Health Med 2005, 11:42-49.
183. Bilgi N., Bell K., Ananthakrishnan A.N., Atallah E. Imatinib and panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010, 44:926-928.
184. Smith M., Lin K.M., Zheng Y.P., et al. An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng or ginkgo biloba. Clin Pharmacol Ther 2001, 69:p86.
185. Hwang S.W., Han H.S., Lim K.Y., Han J.Y. Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol 2008, 3:942-943.
186. Harkey M.R., Henderson G.L., Gershwin M.E., Stern J.S., Hackman R.M. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001, 73:1101-1106.
187. Smith P.F., Bullock J.M., Booker B.M., Haas C.E., Berenson C.S., Jusko W.J. Induction of imatinib metabolism by hypericum perforatum. Blood 2004, 104:1229-1230.
188. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., Egorin M.J. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004, 76:323-329.
189. Gorski J.C., Huang S.M., Pinto A., et al. The effect of echinacea (Echinacea purpurea root) on cytochrome p450 activity in vivo. Clin Pharmacol Ther 2004, 75:89-100.
190. Ge J., Tan B.X., Chen Y., et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berlin, Germany) 2011, 89:595-602.
191. Thomas-Schoemann A., Alexandre J., Mongaret C., et al. Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study. Bull Cancer 2011, 98:645-653.
192. Lawenda B.D., Kelly K.M., Ladas E.J., Sagar S.M., Vickers A., Blumberg J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapyα. J Natl Cancer Inst 2008, 100:773-783.
193. Coriat R., Nicco C., Chereau C., et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012, 11:2284-2293.
194. Orcutt K.P., Parsons A.D., Sibenaller Z.A., et al. Erlotinib-mediated inhibition of egfr signaling induces metabolic oxidative stress through Nox4. Cancer Res 2011, 71:3932-3940.
195. Boudou-Rouquette P., Ropert S., Mir O., et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 2012, 17:1204-1212.
196. Arrondeau J., Mir O., Boudou-Rouquette P., et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2012, 30:2046-2049.
197. Gao B., Yeap S., Clements A., Balakrishnar B., Wong M., Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012, 30:4017-4025.
198. FDA, 2011. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm080499.htm.
199. Maki R.G., D'Adamo D.R., Keohan M.L., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27(19):3133-3140.
200. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(13):3267-3279.
201. Li J., Karlsson M.O., Brahmer J., et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006, 98(23):1714-1723.
202. Bouchet S., Titier K., Moore N., et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 2012.
203. O'Donnell A., Faivre S., Burris H.A, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26(10):1588-1595.
204. Boni J.P., Hug B., Leister C., Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 2009, 36(Suppl. 3):S18-S25.